Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Aiko Biotechnology Inc.
DescriptionIV neutral opioid antagonist
Molecular Target Mu opioid receptor (MOR) (OPRM1)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationConstipation
Indication DetailsTreat opioid-induced constipation (OIC)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today